Asahi Kasei Acquires Aicuris Anti-infective Cures AG

Asahi Kasei Acquires Calliditas Therapeutics

September 2, 2024

Biotechnology

Asahi Kasei Corporation completed a recommended public cash offer for Calliditas Therapeutics AB, acquiring 93.30% of the outstanding shares and ADSs as of settlement. Asahi Kasei intends to convert ADSs, commence a compulsory buy-out of remaining shares, and pursue delisting of Calliditas from Nasdaq Stockholm and suspension/delisting of ADSs in the U.S.

Asahi Kasei Medical to Acquire Bionova Scientific

April 14, 2022

Healthcare Services

Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.

Curi Bio Acquires South Korea-based Quvit Bio

January 12, 2026

Biotechnology

Curi Bio completed a full acquisition of South Korea-based Quvit Bio and has established Curi Bio Co., Ltd. as its Asia-Pacific commercial and operational hub. The deal integrates Quvit's imaging hardware, software and team to expand Curi Bio's localized sales, R&D and operational capabilities across South Korea, Japan and China.

Chugai Pharmaceutical to Acquire Renalys Pharma

October 24, 2025

Biotechnology

Chugai Pharmaceutical Co., Ltd. will acquire Renalys Pharma, Inc. through a definitive stock purchase agreement. The transaction includes an upfront payment of JPY 15.0 billion and potential earn-outs of up to JPY 16.0 billion tied to regulatory and sales milestones for sparsentan in Japan, South Korea, and Taiwan.

Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights

October 15, 2025

Pharmaceuticals

Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.